<DOC>
	<DOCNO>NCT02483078</DOCNO>
	<brief_summary>This Phase 2b/3 , multi-center , two part study , design evaluate efficacy , safety , tolerability PRO 140 conjunction exist ART ( fail regimen ) one week Optimized Background Therapy ( OBT ) 24 week respectively . Study population include treatment-experienced HIV-infected patient CCR5-tropic virus demonstrate evidence HIV-1 replication despite ongoing antiretroviral therapy document genotypic phenotypic resistance ART drug within three drug class ( within two drug class limit treatment option ) .The option may limit result drug antiviral class cross-resistance document treatment intolerance .</brief_summary>
	<brief_title>A Randomized , Double-blind , Placebo-controlled Trial , Followed Single-arm Treatment PRO 140 Combination w/ Optimized Background Therapy Treatment-Experienced HIV Subjects</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<criteria>1 . Males female , age ≥ 18 year 2 . Exclusive CCR5tropic virus Screening Visit 3 . Have history least 3 month current antiretroviral regimen 4 . Treatmentexperienced HIVinfected patient document genotypic phenotypic resistance least one ART drug within three drug class OR Treatmentexperienced HIVinfected patient document genotypic phenotypic resistance least one ART drug within two drug class limit treatment option . The option may limit result drug antiretroviral class crossresistance document treatment intolerance . 5 . Be willing remain treatment without change addition OBT regimen , except toxicity management upon meet criterion treatment failure . 6 . Plasma HIV1 RNA ≥ 400 copies/mL Screening Visit document detectable viral load ( HIV1 RNA &gt; 50 copies/ml ) within last 3 month prior Screening Visit . 7 . Laboratory value Screening : Absolute neutrophil count ( ANC ) ≥ 750/mm3 Hemoglobin ( Hb ) ≥ 10.5 gm/dL ( male ) ≥ 9.5 gm/dL ( female ) Platelets ≥ 75,000 /mm3 Serum alanine transaminase ( SGPT/ALT ) &lt; 5 x upper limit normal ( ULN ) Serum aspartate transaminase ( SGOT/AST ) &lt; 5 x ULN Bilirubin ( total ) &lt; 2.5 x ULN unless Gilbert 's disease present subject receive atazanavir absence evidence significant liver disease Creatinine ≤ 1.5 x ULN 8 . Clinically normal rest 12lead ECG Screening Visit , abnormal , consider clinically significant Principal Investigator 9 . Both male female patient partner childbearing potential must agree use 2 medically accept method contraception ( e.g. , barrier contraceptive [ male condom , female condom , diaphragm spermicidal gel ] , hormonal contraceptive [ implant , injectables , combination oral contraceptive , transdermal patch , contraceptive ring ] , intrauterine device ) course study ( exclude woman childbearing potential men sterilize ) . Females childbearing potential must negative serum pregnancy test Screening visit negative urine pregnancy test prior receive first dose study drug . 10 . Willing able participate aspect study , include use SC medication , completion subjective evaluation , attendance schedule clinic visit , compliance protocol requirement evidence provide write informed consent . Note : Subjects diagnose either substance dependence substance abuse history concomitant condition ( e.g. , medical , psychologic , psychiatric ) may enrol opinion site investigator circumstance would interfere subject 's successful completion study requirement . 1 . Documented CXCR4tropic virus Dual/Mixed tropic ( R5X4 ) virus 2 . Patients viable treatment option ( ≤ 1 fully active approve drug ) 3 . Any active infection malignancy require acute therapy ( exception local cutaneous Kaposi 's sarcoma ) Note : Subjects infect hepatitis B virus early stage hepatitis C virus eligible study . 4 . Laboratory test value ≥ grade 3 DAIDS laboratory abnormality exception absolute CD4+ count criterion &lt; 200/mm3 5 . Females pregnant , lactating , breastfeeding , plan become pregnant study 6 . Unexplained fever clinically significant illness within 1 week prior first study dose 7 . Any vaccination within 2 week prior first study dose . 8 . Subjects weigh &lt; 35kg 9 . History anaphylaxis 10 . History Bleeding Disorder patient anticoagulant therapy 11 . Prior use maraviroc CCR5 coreceptor antagonist 12 . Participation experimental drug trial ( ) within 30 day Screening Visit study 13 . Any known allergy antibody study drug excipients 14 . Treatment follow : Radiation cytotoxic chemotherapy 30 day prior Screening Visit study Immunosuppressants within 60 day prior Screening Visit study Immunomodulating agent ( e.g. , interleukin , interferon ) , hydroxyurea , foscarnet within 60 day prior Screening Visit study Oral parenteral corticosteroid within 30 day prior Screening Visit study . Subjects chronic steroid therapy &gt; 5 mg/day exclude follow exception : Subjects inhale , nasal , topical steroid exclude . 15 . Any clinical condition , Investigator 's judgment , would potentially compromise study compliance ability evaluate safety/efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>